Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.

September 29, 2014
PresentationFiclatuzumab

ESMO 2014: Efficacy analysis of gefitinib +/- ficlatuzumab in serum proteomic-based subgroups of patients with previously untreated lung adenocarcinoma

September 29, 2014
PresentationTivozanib

ESMO 2014: Phase 2 clinical evaluation of preclinically defined biomarkers for vascular endothelial growth factor tyrosine kinase inhibitor tivozanib in renal cell carcinoma

October 20, 2013
PublicationTivozanib

Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

Authors: Robert J. Motzer, Dmitry Nosov, Timothy Eisen, Igor Bondarenko, Vladimir Lesovoy, Oleg Lipatov, Piotr Tomczak, Oleksiy Lyulko, Anna Alyasova, Mihai Harza, Mikhail Kogan, Boris Y. Alekseev, Cora N. Sternberg, Cezary Szczylik, David Cella, Cristina Ivanescu, Andrew Krivoshik, Andrew Strahs, Brooke Esteves, Anna Berkenblit, Thomas E. Hutson. Click here for link to article.

February 24, 2013
PresentationTivozanib

ASCO 2013: Efficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib

February 16, 2013
PresentationTivozanib

ASCO GU 2013: Subgroup analyses of a Phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC)

February 16, 2013
PresentationTivozanib

ASCO GU 2013: Treatment benefit of tivozanib hydrochloride vs sorafenib on health-related quality of life among patients with advanced/metastatic renal cell carcinoma (mRCC): TIVO-1 study results

1 … 7 8 9 10 11 … 14

Looking for medical information? Contact our Medical Information Team at

AVEOmedicalinformation@aveooncology.com.